How biomarkers can improve clinical drug development

American Pharmaceutical Review

Volumn 7, Issue 3, 2004, Pages 62-64

  Jadhav, P R ^a,b   Mehta, M U ^a   Gobburu, J V S ^a  

^a Center for Drug Evaluation/Research   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DOFETILIDE; DUTASTERIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; METOPROLOL; PERINDOPRIL; SOTALOL; TRASTUZUMAB; WARFARIN;

ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG QUALITY; DRUG RELEASE; DRUG SELECTIVITY; DRUG SYNTHESIS; GENETIC HETEROGENEITY; HEART ARREST; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; POPULATION GENETICS; PROSTATE HYPERTROPHY; TACHYCARDIA; THROMBOEMBOLISM;

EID: 3042780195     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clin Pharmacol Ther 2001; 69(3):89-95.
2. Colburn KA. Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing. J Clin Pharmacol 2003; 43(4): 329-341.
3. Ferber G. Biomarkers and Proof of Concept. Methods Find Exp Clin Pharmacol 2002; 24 Suppl C:35-40.
4. Frank R, Hargreaves R. Clinical Biomarkers in Drug Discovery and Development. Nat Rev Drug Discov 2003; 2(7): 566-580.
5. Rolan P, Atkinson AJ, Jr., Lesko LJ. Use of Biomarkers from Drug Discovery Through Clinical Practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin Pharmacol Ther 2003; 73(4): 284-291.
6. Emilien G, van Meurs W, Maloteaux JM. The Dose-response Relationship in Phase I Clinical Trials and Beyond: Use, Meaning, and Assessment. Pharmacol Ther 2000; 88(1):33-58.
7. Gobburu JVS. Rational Dose-finding Approaches that Contribute to Regulatory Decision Making and Labeling.: Clinical Development of Oncologic Agents: Challenging the Tradition, Georgetown University Medical Center Washington DC, 2003.
8. Temple RJ. Evolution, Current Approaches and Regulatory Expectations for Characterization of Dose- and exposure-response Relationship for New Drugs.: 39th DIA Annual Meeting, San Antonio, TX, 2003.
9. http://www.fda.gov/cder/guidance/addendum.htm Clinical development and labeling of anti-infective drug products- points to consider. Access date (11-28-2003)
10. http://www.fda.gov/cder/guidance/5341fn1.pdf Exposure-response relationships- study design, data analysis and regulatory applications. Access date (11-23-2003)
11. http://www.fda.gov/cder/guidance/iche4.pdf Dose response information to support drug registration. Access date (11-23-2003)
12. Palmer AM. Cholinergic Therapies for Alzheimer's Disease: Progress and Prospects. Curr Opin Investig Drugs 2003; 4(7):820-825.
13. Fox KM. Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients with Stable Coronary Artery Disease: Randomized, Double-blind, Placebo-controlled, Multicentre Trial (the EUROPA study). Lancet 2003; 362(9386):782-788.
14. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A Model for the Turnover of Dihydrotestosterone in the Presence of the Irreversible 5 Alpha-reductase Inhibitors GI198745 and Finasteride. Clin Pharmacol Ther 1998; 64(6):636-647.
15. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY et al. Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-methyltransferase Gene Locus. J Natl Cancer Inst 1999; 91(23):2001-2008.
16. Baselga J. Herceptin Alone or in Combination with Chemotherapy in the Treatment of HER2-positive Metastatic Breast Cancer: Pivotal Trials. Oncology 2001; 61 Suppl 2:14-21.
17. Johnson JR, Williams G, Pazdur R. End Points and United States Food and Drug Administration Approval of Oncology Drugs. J Clin Oncol 2003; 21(7):1404-1411.
18. http://www.fda.gov/cder/guidance/3647fnl.pdf Antiretroviral drugs using plasma HIV RNA measurements- clinical eonsiderations for accelerated and traditional approval- guidance for industry. Access date (11-26-2003)
19. http://www.gov/cder/guidance/1397fnl.pdf Providing clinical evidence of effectiveness for human drug and biological products. Access date (12-12-2003)
20. http://www.fda.gov/cder/pediatric/labels/sotalol.pdf BETAPACE (Sotalol hydrochloride) Label. Access date (11-25-2003)
21. Abrahamsson B, Lucker P, Olofsson B, Regardh CG, Sandberg A, Wieselgren I et al. The Relationship Between Metoprolol Plasma Concentration and Beta 1-blockade in Healthy Subjects: a Study on Conventional Metoprolol and Metoprolol CR/ZOK Formulations. J Clin Pharmacol 1990; 30(2 Suppl):S46-S54.
22. Chen ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D et al. Bioavailability and Bioequivalence: an FDA Regulatory Overview. Pharm Res 2001; 18(12):1645-1650.